argenex SE $ARGX Shares Sold by Oddo BHF Asset Management Sas

Oddo BHF Asset Management Sas lowered its holdings in argenex SE (NASDAQ:ARGX) by 18.7% in the 4th quarter, Holdings Channel.com reports. The fund owned 23,473 shares of the company’s stock after selling 5,416 shares during the quarter. Oddo BHF Asset Management Sas’ holdings in argenex were worth $19,740,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Abound Wealth Management increased its position in shares of argenex by 3,200.0% in the fourth quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after acquiring an additional 32 shares in the last quarter. Sound Income Strategies LLC acquired a new stake in shares of argenex in the fourth quarter worth $28,000. Ameriflex Group Inc. acquired a new stake in shares of argenex in the third quarter worth $32,000. Aventura Private Wealth LLC acquired a new stake in shares of argenex in the fourth quarter worth $38,000. Finally, Sunbelt Securities Inc. acquired a new stake in shares of argenex in the third quarter worth $36,000. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenex Price Performance

NASDAQ ARGX opened at $884.20 on Tuesday. argenex SE has a 12 month low of $510.05 and a 12 month high of $934.62. The company has a market capitalization of $54.99 billion, a price-to-earnings ratio of 39.37, a price-to-earnings-growth ratio of 1.37 and a beta of 0.47. The company’s fifty day moving average price is $814.84 and its two-hundred day moving average price is $811.27.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. The firm had revenue of $1.31 billion for the quarter. As a group, analysts anticipate that argenex SE will post 26.19 EPS for the current year.

Analyst Ratings Changes

ARGX has been the subject of several recent research reports. Glj Research raised shares of argenex to a “strong-buy” rating in a research report on Friday, April 3rd. HC Wainwright raised their price target on shares of argenex from $915.00 to $940.00 and gave the company a “buy” rating in a report on Friday, February 27th. Royal Bank Of Canada lowered their price target on shares of argenex from $925.00 to $890.00 and set an “outperform” rating for the company in a report on Friday, February 27th. Wall Street Zen lowered shares of argenex from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Finally, Robert W. Baird raised their price target on shares of argenex from $858.00 to $867.00 and gave the company a “neutral” rating in a report on Friday, February 27th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,019.50.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.